Generation of human islet-specific regulatory T cells by TCR gene transfer

Journal of Autoimmunity

Volumn 79, Issue , 2017, Pages 63-73

  Hull, Caroline M ^a,e   Nickolay, Lauren E ^a,e   Estorninho, Megan ^a,e   Richardson, Max W ^b   Riley, James L ^b   Peakman, Mark ^a,c,d,e   Maher, John ^e,f,g   Tree, Timothy I M ^a,e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Peak Therapeutics   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f GUY S HOSPITAL   (United Kingdom)

^g KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cell therapy; Diabetes; Regulatory T cells; TCR gene therapy

Indexed keywords

CD69 ANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR;

ALLELE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; GENE TRANSFER; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; JURKAT CELL LINE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NUCLEOTIDE SEQUENCE; PANCREAS ISLET CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; UPREGULATION; ANIMAL; CELL LINE; DISEASE MODEL; GENE ORDER; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; LENTIVIRINAE; METABOLISM; MOUSE; PANCREAS ISLET;

ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; GENE ORDER; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; ISLETS OF LANGERHANS; JURKAT CELLS; LENTIVIRUS; MICE; RECEPTORS, ANTIGEN, T-CELL; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, REGULATORY; TRANSDUCTION, GENETIC;

EID: 85009809566     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2017.01.001     Document Type: Article

References (45)

1. [1] Atkinson, M.A., Eisenbarth, G.S., Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358 (2001), 221–229.
2. [2] Zheng, Y., Rudensky, A.Y., Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8 (2007), 457–462.
3. [3] Brusko, T.M., Wasserfall, C.H., Clare-Salzler, M.J., Schatz, D.A., Atkinson, M.A., Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 54 (2005), 1407–1414.
4. [4] Lindley, S., Dayan, C.M., Bishop, A., Roep, B.O., Peakman, M., Tree, T.I., Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 (2005), 92–99.
5. [5] Glisic-Milosavljevic, S., Wang, T., Koppen, M., Kramer, J., Ehlenbach, S., Waukau, J., et al. Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes. Clin. Exp. Immunol. 150 (2007), 75–82.
6. [6] Glisic-Milosavljevic, S., Waukau, J., Jailwala, P., Jana, S., Khoo, H.J., Albertz, H., et al. At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS One, 2, 2007, e146.
7. [7] Fang, Y., Christopher-Hennings, J., Brown, E., Liu, H., Chen, Z., Lawson, S.R., et al. Development of genetic markers in the non-structural protein 2 region of a US type 1 porcine reproductive and respiratory syndrome virus: implications for future recombinant marker vaccine development. J. Gen. Virol. 89 (2008), 3086–3096.
8. [8] Riley, J.L., June, C.H., Blazar, B.R., Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30 (2009), 656–665.
9. [9] Trzonkowski, P., Szarynska, M., Mysliwska, J., Mysliwski, A., Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytom. Part A J. Int. Soc. Anal. Cytol. 75 (2009), 175–188.
10. [10] Solh, M., Brunstein, C., Morgan, S., Weisdorf, D., Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant. 17 (2011), 710–716.
11. [11] Di Ianni, M., Falzetti, F., Carotti, A., Terenzi, A., Castellino, F., Bonifacio, E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117 (2011), 3921–3928.
12. [12] Marek-Trzonkowska, N., Mysliwiec, M., Dobyszuk, A., Grabowska, M., Derkowska, I., Juscinska, J., et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin. Immunol. 153 (2014), 23–30.
13. [13] Marek-Trzonkowska, N., Mysliwiec, M., Dobyszuk, A., Grabowska, M., Techmanska, I., Juscinska, J., et al. Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 35 (2012), 1817–1820.
14. [14] Bluestone, J.A., Buckner, J.H., Fitch, M., Gitelman, S.E., Gupta, S., Hellerstein, M.K., et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7 (2015), 315–389.
15. [15] Ozdal, O.L., Aprikian, A.G., Begin, L.R., Behlouli, H., Tanguay, S., Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. BJU Int. 93 (2004), 970–974 discussion 4.
16. [16] Masteller, E.L., Warner, M.R., Tang, Q., Tarbell, K.V., McDevitt, H., Bluestone, J.A., Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J. Immunol. 175 (2005), 3053–3059.
17. [17] Kirsch, D.G., Tarbell, N.J., New technologies in radiation therapy for pediatric brain tumors: the rationale for proton radiation therapy. Pediatr. Blood Cancer 42 (2004), 461–464.
18. [18] Tarbell, K.V., Petit, L., Zuo, X., Toy, P., Luo, X., Mqadmi, A., et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204 (2007), 191–201.
19. [19] Putnam, A.L., Safinia, N., Medvec, A., Laszkowska, M., Wray, M., Mintz, M.A., et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 13 (2013), 3010–3020.
20. [20] Tsang, J.Y., Tanriver, Y., Jiang, S., Xue, S.A., Ratnasothy, K., Chen, D., et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J. Clin. Investig. 118 (2008), 3619–3628.
21. [21] Brusko, T.M., Koya, R.C., Zhu, S., Lee, M.R., Putnam, A.L., McClymont, S.A., et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One, 5, 2010, e11726.
22. [22] Plesa, G., Zheng, L., Medvec, A., Wilson, C.B., Robles-Oteiza, C., Liddy, N., et al. TCR affinity and specificity requirements for human regulatory T-cell function. Blood 119 (2012), 3420–3430.
23. [23] Tree, T.I., Lawson, J., Edwards, H., Skowera, A., Arif, S., Roep, B.O., et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 59 (2010), 1451–1460.
24. [24] Brochet, X., Lefranc, M.P., Giudicelli, V., IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36 (2008), W503–W508.
25. [25] Giudicelli, V., Brochet, X., Lefranc, M.P., IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb. Protoc. 2011 (2011), 695–715.
26. [26] Zennou, V., Perez-Caballero, D., Gottlinger, H., Bieniasz, P.D., APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78 (2004), 12058–12061.
27. [27] Battaglia, M., Stabilini, A., Draghici, E., Gregori, S., Mocchetti, C., Bonifacio, E., et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 55 (2006), 40–49.
28. [28] Scotta, C., Esposito, M., Fazekasova, H., Fanelli, G., Edozie, F.C., Ali, N., et al. Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica 98 (2013), 1291–1299.
29. [29] Putnam, A.L., Brusko, T.M., Lee, M.R., Liu, W., Szot, G.L., Ghosh, T., et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58 (2009), 652–662.
30. [30] D'Alise, A.M., Amabile, G., Iovino, M., Di Giorgio, F.P., Bartiromo, M., Sessa, F., et al. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol. Cancer Ther. 7 (2008), 1140–1149.
31. [31] Schneider, A., Rieck, M., Sanda, S., Pihoker, C., Greenbaum, C., Buckner, J.H., The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 181 (2008), 7350–7355.
32. [32] Herold, K.C., Gitelman, S.E., Willi, S.M., Gottlieb, P.A., Waldron-Lynch, F., Devine, L., et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 56 (2013), 391–400.
33. [33] Rigby, M.R., DiMeglio, L.A., Rendell, M.S., Felner, E.I., Dostou, J.M., Gitelman, S.E., et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 1 (2013), 284–294.
34. [34] Haller, M.J., Gitelman, S.E., Gottlieb, P.A., Michels, A.W., Rosenthal, S.M., Shuster, J.J., et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J. Clin. Investig. 125 (2015), 448–455.
35. [35] Salomon, B., Lenschow, D.J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000), 431–440.
36. [36] Tarbell, K.V., Yamazaki, S., Olson, K., Toy, P., Steinman, R.M., CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199 (2004), 1467–1477.
37. [37] Golab, K., Krzystyniak, A., Marek-Trzonkowska, N., Misawa, R., Wang, L.J., Wang, X., et al. Impact of culture medium on CD4(+) CD25(high)CD127(lo/neg) Treg expansion for the purpose of clinical application. Int. Immunopharmacol. 16 (2013), 358–363.
38. [38] Thomas, S., Xue, S.A., Cesco-Gaspere, M., San Jose, E., Hart, D.P., Wong, V., et al. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J. Immunol. 179 (2007), 5803–5810.
39. [39] Kuball, J., Dossett, M.L., Wolfl, M., Ho, W.Y., Voss, R.H., Fowler, C., et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109 (2007), 2331–2338.
40. [40] Cohen, C.J., Li, Y.F., El-Gamil, M., Robbins, P.F., Rosenberg, S.A., Morgan, R.A., Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67 (2007), 3898–3903.
41. [41] Scholten, K.B., Kramer, D., Kueter, E.W., Graf, M., Schoedl, T., Meijer, C.J., et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 119 (2006), 135–145.
42. [42] de Witte, M.A., Jorritsma, A., Kaiser, A., van den Boom, M.D., Dokter, M., Bendle, G.M., et al. Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol. 181 (2008), 5128–5136.
43. [43] Tsang, J.Y., Ratnasothy, K., Li, D., Chen, Y., Bucy, R.P., Lau, K.F., et al. The potency of allospecific Tregs cells appears to correlate with T cell receptor functional avidity. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 11 (2011), 1610–1620.
44. [44] Cheng, K., Chen, Q., Yang, X., Gao, S., Yu, H., Classification of imbalanced bioinformatics data by using boundary movement-based ELM. Biomed. Mater Eng. 26:Suppl. 1 (2015), S1855–S1862.
45. [45] Beringer, D.X., Kleijwegt, F.S., Wiede, F., van der Slik, A.R., Loh, K.L., Petersen, J., et al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. Nat. Immunol. 16 (2015), 1153–1161.